Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2013

View Archived Issues

New milestone under Ono Pharmaceutical and Receptos' GPCR collaboration

Novel nanoparticles shown to suppress choroidal neovascularization

Sirolimus demonstrates safety in patients with uveitis

ADMA Biologics begins pivotal phase III study of RI-002 in PIDD

Hangzhou Bensheng Pharmaceutical divulges novel agents for cancer

GlaxoSmithKline synthesizes bromodomain-containing protein inhibitor

reMYND patents new agents for tauopathies

Janssen and Bayer launch global cardiovascular research program for Xarelto

Incyte Corp. prepares new series of JAK1 inhibitors

Vitamin D deficiency associated with psoriasis severity

New mutations identified in Gorlin-Goltz syndrome

Norendoxifen as a new lead compound for aromatase inhibitor development

Researchers at Piramal Imaging design new diagnostics for thrombosis

Cellceutix plans future Kevetrin trials

Merck & Co. submits BLA for ragweed AIT

Non-inferiority reported in phase III trial of the seasonal flu vaccine ASP-7374

Theravance grants Clinigen exclusive commercialization rights to Vibativ in the E.U.

Retrophin reports data from preclinical studies of RE-024

Amgen synthesizes novel sodium channel blockers

Aeterna Zentaris to stop phase III trial of combination regimen using perifosine

Sosei initiates phase III study of mucoadhesive buccal tablet for oropharyngeal candidiasis

ZIOPHARM Oncology begins phase II study of Ad-RTS IL-12 combined with palifosfamide

Autologous CDC therapy proves to be safe and effective in patients post-MI

TONIX Pharmaceuticals and the FDA discuss NDA plan for TNX-102

NeuroVive acquires novel cyclophilin inhibitors from Biotica

Astellas and Ambit terminate collaboration for FLT3 kinase inhibitors

Telormedix commences enrollment in phase II trial in bladder cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...